Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794525 | Ophthalmology Retina | 2018 | 6 Pages |
Abstract
Five years after initiating treatment with ranibizumab or bevacizumab in CATT participants, worse baseline VA, larger baseline CNV lesion area, and presence of baseline RPE elevation remained independently associated with worse VA at 5 years. In addition, male gender, cigarette smoking, and absence of subretinal fluid and treatment with ranibizumab in the first 2 years were independently associated with worse vision outcomes at 5 years.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Gui-shuang PhD, Maureen G. PhD, Wei MS, Juan E. MD, Ebenezer MBBS, PhD, Glenn J. MD, Cynthia A. MD, Stephanie A. PhD, Daniel F. MD, Comparison of AMD Treatments Trials Research Group Comparison of AMD Treatments Trials Research Group,